Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells.
## Primary Indications
* Healing of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
* Usual GERD symptom relief (off-label for treatment of GERD without erosive esophagitis).
## Adult Dosing
* **Healing of Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions:** Starting dose 40 mg orally twice daily. Doses can be titrated up to 240 mg daily (divided doses).
* **Symptomatic GERD (off-label):** 20 mg to 40 mg orally once daily.
## Pediatric Dosing
* **Erosive Esophagitis (1-16 years):** 20 mg to 40 mg orally once daily depending on weight and severity.
* 15 kg to < 40 kg: 20 mg once daily.
* ≥ 40 kg: 40 mg once daily.
* **Maintenance of Healing (5-16 years):** 20 mg to 40 mg orally once daily.
* **Note:** Pediatric dosing for other indications is not well-established and typically off-label. Consult specific pediatric guidelines.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg orally once daily for severe hepatic impairment.
* **Renal Impairment:** No dose adjustment generally required.
## Contraindications
* Known hypersensitivity to pantoprazole or any excipients in the formulation.
* Concomitant use with Rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness.
* **Serious:**
* **Clostridium difficile-associated diarrhea (CDAD):** PPI use may increase the risk.
* **Bone fracture:** Long-term use may be associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine.
* **Hypomagnesemia:** Can occur with prolonged use (≥1 year), leading to fatigue, dizziness, muscle spasms, tetany, seizures, and arrhythmias.
* **Vitamin B12 deficiency:** May occur with prolonged use.
* **Fundic gland polyps:** More common with long-term use.
* **Systemic lupus erythematosus (SLE):** New or exacerbation of existing SLE.
## Key Drug Interactions
* **Rilpivirine:** Contraindicated due to increased risk of virologic failure.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May affect metabolism of drugs like clopidogrel, voriconazole, and others.
* **Ketoconazole, Itraconazole, Posaconazole:** Decreased absorption due to increased gastric pH.
* **Iron Salts, Mycophenolate Mofetil, Dasatinib:** Decreased absorption due to increased gastric pH.
* **St. John's Wort, Rifampin:** May decrease pantoprazole plasma concentrations.
## Monitoring
* Electrolytes (especially magnesium, calcium, potassium) with prolonged therapy.
* Bone mineral density if risk factors for osteoporosis are present.
* Symptoms of B12 deficiency.
* Assess for signs and symptoms of CDAD.
## Clinical Pearls
* PPIs should be used at the lowest effective dose for the shortest duration needed.
* For optimal absorption, pantoprazole delayed-release tablets should be taken at least 1 hour before a meal.
* Pantoprazole oral suspension should be administered at least 30 minutes before a meal.
* Do not crush or chew delayed-release tablets.
---
***Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and recommendations may vary based on individual patient factors and local protocols.*
